M rie C, K ber L, Skov Olsen P, Andersson C, Gislason G, Skov Jensen J, Torp-Pedersen C. Association of warfarin therapy duration after bio- prosthetic aortic valve replacement with risk of mortality, thromboem- bolic complications, and bleeding. JAMA. 2012;308:2118 2125. doi: 471. Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, et al; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: in- terim results from the prospective randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational de- vice exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202 1210. doi: 472. Torella M, Torella D, Chiodini P, Franciulli M, Romano G, De Santo L, De Feo M, Amarelli C, Sasso FC, Salvatore T, et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the LOWERING-IT Trial. Am Heart J. 473. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 474. Barnett HJ, Boughner DR, Taylor DW, Cooper PE, Kostuk WJ, Nichol PM. Further evidence relating mitral-valve prolapse to cerebral isch- emic events. N Engl J Med. 1980;302:139 144. doi: 10.1056/ 475. Freed LA, Levy D, Levine RA, Larson MG, Evans JC, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341:1 7. doi: 10.1056/NEJM199907013410101 476. Gilon D, Buonanno FS, Joffe MM, Leavitt M, Marshall JE, Kistler JP, Levine RA. Lack of evidence of an association between mitral-valve pro- lapse and stroke in young patients. N Engl J Med. 1999;341:8 13. doi: 477. 